Quality & complianceOfficial

Novo Nordisk to permanently withdraw Victoza pre-filled pen from Danish market from late February 2027

🇩🇰 DKMA · Mon 02 Nov 2026

The Danish Medicines Agency lists the end of Victoza (liraglutide) 6 mg/ml pre-filled pen marketing as a permanent cessation for commercial reasons.

The Danish Medicines Agency (DKMA) has published a supply notice stating that Novo Nordisk A/S will stop marketing Victoza 6 mg/ml solution for injection in pre-filled pen. The notice is dated 2 November 2026 and appears among the agency's announcements on medicines supply.

The active substance is liraglutide (ATC code A10BJ02). DKMA gives the expected period as from the end of February 2027 and states the reason as commercial. The additional information field describes the measure as a permanent market cessation.

The notice does not say whether any other Victoza presentation is affected, nor does it mention replacement products, stock levels or the exact date of the last supply. DKMA directs questions about the current status to the company.

Because the item is classed under supply difficulties, the agency treats it as a supply-related notification rather than a safety action.

What it means for your team

  • Supply-chain and market-access teams should plan for the permanent loss of this presentation in Denmark from the end of February 2027.
  • Regulatory and QA staff should check the company's own communications for details, as DKMA's notice gives no stock or last-supply information.
  • Teams handling patient and prescriber communications should prepare continuity-of-treatment messaging, noting the notice does not name alternatives.
  • Pharmacovigilance units should check whether labelling, patient materials or risk-minimisation activities linked to this presentation need updating.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →